JP2024518554A - 置換ヘテロ環化合物 - Google Patents
置換ヘテロ環化合物 Download PDFInfo
- Publication number
- JP2024518554A JP2024518554A JP2023570165A JP2023570165A JP2024518554A JP 2024518554 A JP2024518554 A JP 2024518554A JP 2023570165 A JP2023570165 A JP 2023570165A JP 2023570165 A JP2023570165 A JP 2023570165A JP 2024518554 A JP2024518554 A JP 2024518554A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- amino
- triazol
- carboxamide
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188498P | 2021-05-14 | 2021-05-14 | |
| US63/188,498 | 2021-05-14 | ||
| US202263318149P | 2022-03-09 | 2022-03-09 | |
| US63/318,149 | 2022-03-09 | ||
| PCT/US2022/029102 WO2022241171A1 (en) | 2021-05-14 | 2022-05-13 | Substituted heterocyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518554A true JP2024518554A (ja) | 2024-05-01 |
| JP2024518554A5 JP2024518554A5 (enExample) | 2025-03-12 |
Family
ID=81927926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023570165A Pending JP2024518554A (ja) | 2021-05-14 | 2022-05-13 | 置換ヘテロ環化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11866414B2 (enExample) |
| EP (1) | EP4337655A1 (enExample) |
| JP (1) | JP2024518554A (enExample) |
| KR (1) | KR20240008336A (enExample) |
| AU (1) | AU2022271794A1 (enExample) |
| CA (1) | CA3217332A1 (enExample) |
| CL (1) | CL2023003308A1 (enExample) |
| CO (1) | CO2023015226A2 (enExample) |
| IL (1) | IL308421A (enExample) |
| MX (1) | MX2023013445A (enExample) |
| PE (1) | PE20250262A1 (enExample) |
| TW (1) | TW202311247A (enExample) |
| WO (1) | WO2022241171A1 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024518555A (ja) * | 2021-05-14 | 2024-05-01 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
| JP2024518556A (ja) * | 2021-05-14 | 2024-05-01 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
| JP2024518792A (ja) * | 2021-05-14 | 2024-05-02 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
| JP2024518791A (ja) * | 2021-05-14 | 2024-05-02 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102858043B1 (ko) * | 2018-10-30 | 2025-09-10 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물 |
| WO2021226208A2 (en) | 2020-05-05 | 2021-11-11 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| KR102698413B1 (ko) | 2020-05-05 | 2024-08-26 | 뉴베일런트, 아이엔씨. | 헤테로방향족 거대환식 에터 화학치료제 |
| CN122520625A (zh) | 2020-12-22 | 2026-08-07 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物及其制备方法和用途 |
| US12668594B2 (en) | 2020-12-23 | 2026-06-30 | Sudo Biosciences Limited | TYK2 inhibitors and uses thereof |
| KR20230159421A (ko) | 2021-02-19 | 2023-11-21 | 수도 바이오사이언시즈 리미티드 | Tyk2 억제제 및 이의 용도 |
| TW202302583A (zh) | 2021-02-19 | 2023-01-16 | 英商蘇多生物科學有限公司 | Ｔｙｋ２抑制劑及其用途 |
| IL305119A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | Tyk2 inhibitors and uses thereof |
| WO2022212489A1 (en) | 2021-03-31 | 2022-10-06 | Xinthera, Inc. | Mk2 inhibitors and uses thereof |
| PE20250262A1 (es) * | 2021-05-14 | 2025-01-29 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos |
| CN115724830A (zh) * | 2021-08-31 | 2023-03-03 | 浙江文达医药科技有限公司 | 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法 |
| TW202320768A (zh) | 2021-10-01 | 2023-06-01 | 美商努法倫特公司 | 雜芳族大環醚化合物之固體形式、醫藥組成物及製備 |
| CN117263913A (zh) | 2022-06-20 | 2023-12-22 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物、固体形式、制备方法及其用途 |
| WO2024044486A1 (en) * | 2022-08-22 | 2024-02-29 | Ajax Therapeutics, Inc. | Jak2 inhibitor compounds |
| CN120152968A (zh) * | 2022-11-08 | 2025-06-13 | 百时美施贵宝公司 | 取代的杂环化合物 |
| CN118812511A (zh) * | 2023-04-21 | 2024-10-22 | 浙江文达医药科技有限公司 | 作为tyk2抑制剂的杂环化合物及合成和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016506369A (ja) * | 2012-11-08 | 2016-03-03 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なアミド置換ヘテロ環式化合物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3601268T (lt) | 2017-03-30 | 2021-05-25 | Bristol-Myers Squibb Company | 6-(ciklopropanamido)-4-((2-metoksi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazino-3-karboksamido gavimo būdas |
| PE20250262A1 (es) * | 2021-05-14 | 2025-01-29 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos |
-
2022
- 2022-05-13 PE PE2023003027A patent/PE20250262A1/es unknown
- 2022-05-13 US US17/743,557 patent/US11866414B2/en active Active
- 2022-05-13 AU AU2022271794A patent/AU2022271794A1/en active Pending
- 2022-05-13 TW TW111118122A patent/TW202311247A/zh unknown
- 2022-05-13 MX MX2023013445A patent/MX2023013445A/es unknown
- 2022-05-13 IL IL308421A patent/IL308421A/en unknown
- 2022-05-13 CA CA3217332A patent/CA3217332A1/en active Pending
- 2022-05-13 EP EP22727672.2A patent/EP4337655A1/en active Pending
- 2022-05-13 WO PCT/US2022/029102 patent/WO2022241171A1/en not_active Ceased
- 2022-05-13 KR KR1020237042720A patent/KR20240008336A/ko active Pending
- 2022-05-13 JP JP2023570165A patent/JP2024518554A/ja active Pending
-
2023
- 2023-11-07 CL CL2023003308A patent/CL2023003308A1/es unknown
- 2023-11-09 CO CONC2023/0015226A patent/CO2023015226A2/es unknown
- 2023-11-30 US US18/524,426 patent/US20240190829A1/en not_active Abandoned
-
2024
- 2024-12-11 US US18/976,869 patent/US20250163004A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016506369A (ja) * | 2012-11-08 | 2016-03-03 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なアミド置換ヘテロ環式化合物 |
Non-Patent Citations (2)
| Title |
|---|
| EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 23(2), JPN7023004398, 2004, pages 151 - 158, ISSN: 0005813247 * |
| MEDICINAL CHEMISTRY, vol. 8(4), JPN7023004397, 2012, pages 753 - 768, ISSN: 0005813248 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024518555A (ja) * | 2021-05-14 | 2024-05-01 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
| JP2024518556A (ja) * | 2021-05-14 | 2024-05-01 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
| JP2024518792A (ja) * | 2021-05-14 | 2024-05-02 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
| JP2024518791A (ja) * | 2021-05-14 | 2024-05-02 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
| JP7818623B2 (ja) | 2021-05-14 | 2026-02-20 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023003308A1 (es) | 2024-04-26 |
| IL308421A (en) | 2024-01-01 |
| US20250163004A1 (en) | 2025-05-22 |
| US20240190829A1 (en) | 2024-06-13 |
| EP4337655A1 (en) | 2024-03-20 |
| US20220411384A1 (en) | 2022-12-29 |
| US11866414B2 (en) | 2024-01-09 |
| BR112023023425A2 (pt) | 2024-01-30 |
| PE20250262A1 (es) | 2025-01-29 |
| WO2022241171A1 (en) | 2022-11-17 |
| KR20240008336A (ko) | 2024-01-18 |
| CO2023015226A2 (es) | 2023-11-20 |
| MX2023013445A (es) | 2023-12-14 |
| AU2022271794A1 (en) | 2024-01-04 |
| CA3217332A1 (en) | 2022-11-17 |
| TW202311247A (zh) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11866414B2 (en) | Substituted heterocyclic compounds | |
| JP7818623B2 (ja) | 置換ヘテロ環化合物 | |
| KR102531036B1 (ko) | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 | |
| EP4337656A1 (en) | Substituted heterocyclic compounds | |
| KR20180081584A (ko) | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 | |
| KR20240008339A (ko) | 치환된 헤테로시클릭 화합물 | |
| KR20190068614A (ko) | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물 | |
| EP3999499B1 (en) | Prodrugs in the modulation of interleukin | |
| CN117794912A (zh) | 经取代的杂环化合物 | |
| CN117321045A (zh) | 经取代的杂环化合物 | |
| BR112023023425B1 (pt) | Compostos heterocíclicos substituídos, composição farmacêutica que os compreende, e usos dos mesmos | |
| EA048690B1 (ru) | Замещенные гетероциклические соединения | |
| EA047032B1 (ru) | Замещенные гетероциклические соединения | |
| KR20250099236A (ko) | 치환된 헤테로시클릭 화합물 | |
| CN117355514A (zh) | 经取代的杂环化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250304 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250304 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251202 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260310 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260709 |